Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)

American Journal of Cardiology

Volumn 105, Issue 1, 2010, Pages 69-76

  Nicholls, Stephen J ^a   Brandrup Wognsen, Gunnar ^b,c   Palmer, Mike ^d   Barter, Philip J ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d KEELE UNIVERSITY   (United Kingdom)

^e HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; SULFONAMIDES;

EID: 72049130254     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.08.651     Document Type: Article

References (14)

1. deLemos A.S., Wolfe M.L., Long C.J., Sivapackianathan R., and Rader D.J. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 106 (2002) 1321-1326
2. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham I., Mancia G., Manger Cats V., Orth-Gomer K., Perk J., Pyorala K., Rodicio J.L., Sans S., Sansoy V., Sechtem U., Silber S., Thomsen T., Wood D., and Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1601-1610
3. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., and Blasetto J.W. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 92 (2003) 152-160
4. Jones P.H., Hunninghake D.B., Ferdinand K.C., Stein E.A., Gold A., Caplan R.J., and Blasetto J.W. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 26 (2004) 1388-1399
5. Jones P.H., McKenney J.M., Karalis D.G., and Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 149 (2005) e1
6. McKenney J.M., Jones P.H., Adamczyk M.A., Cain V.A., Bryzinski B.S., and Blasetto J.W. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 19 (2003) 689-698
7. Brown H., and Prescott R. Applied Mixed Models in Medicine (2006), John Wiley, Hoboken, NJ
8. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
9. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
10. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., and Tuzcu E.M. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
11. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., and DeMaria A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
12. Stewart L.A., Clarke M.J., and Cochrane Working Group. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med 14 (1995) 2057-2079
13. Stewart L.A., and Tierney J.F. To IPD or not to IPD?. Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25 (2002) 76-97
14. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 suppl (2005) 24F-33F